Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

Detected CMS Systems:

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. External Links
  11. Analytics And Tracking
  12. Libraries
  13. CDN Services

We are analyzing https://link.springer.com/article/10.1186/bcr2574.

Title:
Triple-negative breast cancer | Breast Cancer Research
Description:
Perou
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Health & Fitness
  • Education
  • Science

Content Management System {📝}

What CMS is link.springer.com built with?


Link.springer.com is based on PIVOTX.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We see no obvious way the site makes money.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

cancer, breast, tumors, google, scholar, article, patients, cas, metastatic, phase, study, triplenegative, clinical, clin, treatment, combination, brca, growth, therapy, basaloid, showed, chemotherapy, receptor, oncol, response, factor, negative, months, res, inhibitors, survival, paclitaxel, inhibitor, results, iii, disease, abstract, higher, parp, randomized, suppl, tumor, time, epidermal, expression, table, molecular, rates, studies, colleagues,

Topics {✒️}

raf/mek/map kinase inhibitors hsp90 inhibitor pu-h71 org/breast-cancer-research triple-negative breast cancer 'triple-negative' breast cancer small-cell lung cancer recurrent/metastatic breast cancer brca-mutated breast cancer csf-1r-dependent osteolysis node-positive breast cancer called triple-negative phenotype grade iii hand-foot her2-positive breast cancer small-size tumors present org/professionals/physician_gls/f_guidelines cd44+/cd24– tumor cells brca-mutated ovarian cancer cd44+/cd24– phenotype relates brca1/2-mutated ovarian cancer newly diagnosed african-american single-institution compilation compared c-src protein expression glomeruloid microvascular proliferation triple negative state molecularly similar hormone receptor-positive tumors including breast cancer human breast cancer advanced breast cancer src tyrosine kinase tyrosine-kinase inhibitor median disease-free survival metastatic breast cancer metastasic breast carcinoma tyrosine kinase inhibitors specific targeted therapies 3-year disease-free rate her2-negative locally recurrent breast cancer models breast cancer subtypes human breast carcinoma median progression-free survival receive trastuzumab-based therapy invasive breast carcinoma familial breast cancer breast cancer res operable breast cancer triple-negative phenotype embryonic transcription factor targeted therapy

Questions {❓}

  • Rakha EA, Tan DS, Foulkes WD, Ellis IO, Tutt A, Nielsen TO, Reis-Filho JS: Are triple negative tumours and basal-like breast cancer synonymous?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Triple-negative breast cancer
         description:Perou's molecular classification defines tumors that neither express hormone receptors nor overexpress HER2 as triple-negative (TN) tumors. These tumors account for approximately 15% of breast cancers. The so-called basaloid tumors are not always synonymous with TN tumors; they differ in the fact that they express different molecular markers, have a higher histologic grade, and have a worse prognosis. Clinically they occur in younger women as interval cancer, and the risk of recurrence is higher within the first 3 years. Distant recurrences in the brain and visceral metastases are more common than in hormone receptor-positive tumors. Therapeutically, despite being highly chemosensitive, their progression-free time is generally short. In terms of chemotherapeutic treatment, anthracyclines and taxanes are useful drugs, and high response rates have been described for the combination of ixabepilone-capecitabine and platinums. The combination with antiangiogenic drugs has also proven useful. A group of new drugs, poly-(ADP-ribose)-polymerase inhibitors, showed favorable results in TN tumors with BRCA mutation. There are currently several ongoing studies with new drugs including epidermal growth factor receptor inhibitors, c-kit inhibitors, Raf/Mek/Map kinase inhibitors and mTOR inhibitors.
         datePublished:2010-10-22T00:00:00Z
         dateModified:2010-10-22T00:00:00Z
         pageStart:1
         pageEnd:9
         sameAs:https://doi.org/10.1186/bcr2574
         keywords:
            Breast Cancer
            Epidermal Growth Factor Receptor
            Bevacizumab
            Sorafenib
            Metastatic Breast Cancer
            Cancer Research
            Oncology
            Surgical Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2574/MediaObjects/13058_2010_Article_2633_HTML.jpg
         isPartOf:
            name:Breast Cancer Research
            issn:
               1465-542X
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Reinaldo D Chacón
               affiliation:
                     name:Instituto Alexander Fleming
                     address:
                        name:Oncology Department, Instituto Alexander Fleming, Argentina
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:María V Costanzo
               affiliation:
                     name:Instituto Alexander Fleming
                     address:
                        name:Oncology Department, Instituto Alexander Fleming, Argentina
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Triple-negative breast cancer
      description:Perou's molecular classification defines tumors that neither express hormone receptors nor overexpress HER2 as triple-negative (TN) tumors. These tumors account for approximately 15% of breast cancers. The so-called basaloid tumors are not always synonymous with TN tumors; they differ in the fact that they express different molecular markers, have a higher histologic grade, and have a worse prognosis. Clinically they occur in younger women as interval cancer, and the risk of recurrence is higher within the first 3 years. Distant recurrences in the brain and visceral metastases are more common than in hormone receptor-positive tumors. Therapeutically, despite being highly chemosensitive, their progression-free time is generally short. In terms of chemotherapeutic treatment, anthracyclines and taxanes are useful drugs, and high response rates have been described for the combination of ixabepilone-capecitabine and platinums. The combination with antiangiogenic drugs has also proven useful. A group of new drugs, poly-(ADP-ribose)-polymerase inhibitors, showed favorable results in TN tumors with BRCA mutation. There are currently several ongoing studies with new drugs including epidermal growth factor receptor inhibitors, c-kit inhibitors, Raf/Mek/Map kinase inhibitors and mTOR inhibitors.
      datePublished:2010-10-22T00:00:00Z
      dateModified:2010-10-22T00:00:00Z
      pageStart:1
      pageEnd:9
      sameAs:https://doi.org/10.1186/bcr2574
      keywords:
         Breast Cancer
         Epidermal Growth Factor Receptor
         Bevacizumab
         Sorafenib
         Metastatic Breast Cancer
         Cancer Research
         Oncology
         Surgical Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fbcr2574/MediaObjects/13058_2010_Article_2633_HTML.jpg
      isPartOf:
         name:Breast Cancer Research
         issn:
            1465-542X
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Reinaldo D Chacón
            affiliation:
                  name:Instituto Alexander Fleming
                  address:
                     name:Oncology Department, Instituto Alexander Fleming, Argentina
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:María V Costanzo
            affiliation:
                  name:Instituto Alexander Fleming
                  address:
                     name:Oncology Department, Instituto Alexander Fleming, Argentina
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research
      issn:
         1465-542X
      volumeNumber:12
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Instituto Alexander Fleming
      address:
         name:Oncology Department, Instituto Alexander Fleming, Argentina
         type:PostalAddress
      name:Instituto Alexander Fleming
      address:
         name:Oncology Department, Instituto Alexander Fleming, Argentina
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Reinaldo D Chacón
      affiliation:
            name:Instituto Alexander Fleming
            address:
               name:Oncology Department, Instituto Alexander Fleming, Argentina
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:María V Costanzo
      affiliation:
            name:Instituto Alexander Fleming
            address:
               name:Oncology Department, Instituto Alexander Fleming, Argentina
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Oncology Department, Instituto Alexander Fleming, Argentina
      name:Oncology Department, Instituto Alexander Fleming, Argentina

External Links {🔗}(162)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📦}

  • Crossref

7.43s.